VRX up +1.22% percent right now. $VRX High is at 127.70 and the Low 126.21 with current volume of 692,846.
Recent News posted below.
VRX Valeant Pharmaceuticals International Recent Headline News
Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 127.96 (+1.85), VRX.TO: 145.54 (+2.70)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 195.43 (-0.57), VRX: 127.96 (+1.85), DVA: 74.54 (+0.05), GILD: 107.30 (+0.85), SLXP: 93.61 (+2.14), ICPT: 178.62 (+6.03), HUM: 132.52 (+1.94)
These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 195.43 (-0.57), VRX: 127.96 (+1.85), HHC: 147.23 (-2.24), PAH: 25.50 (-0.29), CP: 208.54 (+2.07), APD: 134.89 (-0.05), BKW: 32.28 (-0.32)
Earnings Pulse - Valeant Pharma Intl.
PR Newswire - Fri Nov 07, 8:10AM CST
Investor-Edge.com has issued free earnings review on Valeant Pharmaceuticals International Inc. (NYSE: VRX). On October 20, 2014, the company reported its financial results for Q3 FY14 (period ended September 30, 2014). Click on www.investor-edge.com/FreeReports to read our free earnings review on Valeant Pharmaceuticals International Inc. (Valeant). During Q3 FY14, the pharmaceutical company's net revenue grew 33% on a Y-o-Y basis and its cash EPS saw an increase of 48% from the preceding year quarter. Our free coverage report can be accessed at:
VRX: 127.96 (+1.85)
Valeant Pharmaceuticals International Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 06, 3:58PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $128.38 to a high of $132.79. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $130.03 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 128.02 (+1.91)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 47.69 (+0.88), TSLA: 241.92 (+1.72), VRX: 128.02 (+1.91), KR: 58.48 (+0.68), UN: 38.92 (+0.39), UTX: 109.06 (-0.02), PFE: 30.24 (+0.32), HAL: 53.76 (-0.10), TAP: 76.53 (-0.65), KORS: 69.70 (-0.25), TLT: 118.80 (-0.95), PEP: 96.83 (+0.03), DFS: 65.93 (-0.10), COH: 33.95 (+0.29), SPY: 203.85 (+0.51), QQQ: 101.92 (+0.32), QCOM: 69.85 (+0.59), DIA: 175.91 (+0.33), COST: 137.22 (-0.49), IWM: 116.76 (+0.05), MSFT: 48.89 (+0.21), CBS: 52.04 (+0.73)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 246.49 (+0.58), VRX: 128.02 (+1.91), IRWD: 13.86 (+0.02), AUXL: 32.73 (-0.02)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58), SHPG: 200.51 (+1.93), ABBV: 63.55 (+2.05)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58)
Pershing Square is Handed a Partial Win in Allergan Case
at The Street - Wed Nov 05, 8:14AM CST
Hedge fund can vote its shares at special shareholder meeting regarding Valeant bid, but may still face securities law claims.
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.43 (-0.57), BIIB: 326.05 (+5.30), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58), JAZZ: 173.18 (+2.38), ALXN: 194.40 (+0.59), CELG: 107.77 (+1.32)
Allergan takeover closer?
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Valeant's (VRX) hostile takeover of the Botox maker may be closer now that a federal judge denied Allergan's (AGN) request to stop activist investor Bill Ackman and his Pershing Square Capital Management from voting against board members opposed to...
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91)
Allergan deal inches forward with court's decision
By The Associated Press - AP - Tue Nov 04, 3:59PM CST
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.
VRX: 128.02 (+1.91), VRX.TO: 145.54 (+2.70)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 195.43 (-0.57), TSLA: 241.92 (+1.72), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58), ATHM: 44.38 (+0.75)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91), VRX.TO: 145.54 (+2.70)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 40.18 (-0.05), ENDP: 68.89 (-0.07), VRX: 128.02 (+1.91), PFE: 30.24 (+0.32)
Stock Market News for November 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:10AM CST
Bank of Japan’s unanticipated expansion in monetary stimulus helped benchmarks to finish at record highs on Friday
VRX: 128.02 (+1.91), HAL: 53.76 (-0.10), XOM: 96.39 (-0.20), SLB: 99.18 (+0.45), YHOO: 49.22 (+0.67), GS: 191.58 (+0.87), V: 249.61 (-2.82), CMI: 146.19 (+0.15), CHK: 23.09 (-0.32), MRK: 58.99 (-0.35), EOG: 99.55 (unch), ABBV: 63.55 (+2.05), CAT: 102.40 (+0.64), CVX: 117.86 (-0.94), AAPL: 108.99 (-0.02), MA: 84.79 (-0.01)
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter
PR Newswire - Mon Nov 03, 8:15AM CST
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.
CI: 101.28 (+2.29), VRX: 128.02 (+1.91), BAX: 70.54 (-0.07), CVS: 89.02 (+0.64), REGN: 382.73 (+4.89)
Recent News posted below.
VRX Valeant Pharmaceuticals International Recent Headline News
Valeant Pharmaceuticals Sends Letter To Physician Customers
CNW Group - Fri Nov 07, 4:00PM CST
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today sent a letter to physician customers in order to address misconceptions and clarify how Valeant operates its business.
VRX: 127.96 (+1.85), VRX.TO: 145.54 (+2.70)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 195.43 (-0.57), VRX: 127.96 (+1.85), DVA: 74.54 (+0.05), GILD: 107.30 (+0.85), SLXP: 93.61 (+2.14), ICPT: 178.62 (+6.03), HUM: 132.52 (+1.94)
These Six Stocks Are Driving Bill Ackman's Extraordinary 2014 Run
at The Street - Fri Nov 07, 12:01PM CST
It's been a banner year for billionaire hedge fund magnate Bill Ackman -- especially considering just a handful of companies are propelling his big 2014 run.
AGN: 195.43 (-0.57), VRX: 127.96 (+1.85), HHC: 147.23 (-2.24), PAH: 25.50 (-0.29), CP: 208.54 (+2.07), APD: 134.89 (-0.05), BKW: 32.28 (-0.32)
Earnings Pulse - Valeant Pharma Intl.
PR Newswire - Fri Nov 07, 8:10AM CST
Investor-Edge.com has issued free earnings review on Valeant Pharmaceuticals International Inc. (NYSE: VRX). On October 20, 2014, the company reported its financial results for Q3 FY14 (period ended September 30, 2014). Click on www.investor-edge.com/FreeReports to read our free earnings review on Valeant Pharmaceuticals International Inc. (Valeant). During Q3 FY14, the pharmaceutical company's net revenue grew 33% on a Y-o-Y basis and its cash EPS saw an increase of 48% from the preceding year quarter. Our free coverage report can be accessed at:
VRX: 127.96 (+1.85)
Valeant Pharmaceuticals International Falls 2.38% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 06, 3:58PM CST
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $128.38 to a high of $132.79. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $130.03 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRX: 128.02 (+1.91)
Move Over Federal Reserve, There's a New Central Bank in Town
at The Street - Thu Nov 06, 1:35PM CST
The CNBC "Fast Money" trading panel says the stock market can go higher thanks to lower gasoline prices, improved earnings and the European Central Bank.
WFM: 47.69 (+0.88), TSLA: 241.92 (+1.72), VRX: 128.02 (+1.91), KR: 58.48 (+0.68), UN: 38.92 (+0.39), UTX: 109.06 (-0.02), PFE: 30.24 (+0.32), HAL: 53.76 (-0.10), TAP: 76.53 (-0.65), KORS: 69.70 (-0.25), TLT: 118.80 (-0.95), PEP: 96.83 (+0.03), DFS: 65.93 (-0.10), COH: 33.95 (+0.29), SPY: 203.85 (+0.51), QQQ: 101.92 (+0.32), QCOM: 69.85 (+0.59), DIA: 175.91 (+0.33), COST: 137.22 (-0.49), IWM: 116.76 (+0.05), MSFT: 48.89 (+0.21), CBS: 52.04 (+0.73)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 246.49 (+0.58), VRX: 128.02 (+1.91), IRWD: 13.86 (+0.02), AUXL: 32.73 (-0.02)
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid
at The Street - Thu Nov 06, 8:25AM CST
A hostile takeover bid for Allergen has been Bill Ackman's biggest play of 2014. But he's not the only billionaire with a stake in the Botox battle.
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58), SHPG: 200.51 (+1.93), ABBV: 63.55 (+2.05)
Actavis Beats Q3 Views As Buyout Talk Swirls
at Investor's Business Daily - Wed Nov 05, 5:45PM CST
Generic and specialty drug giant Actavis beat Wall Street's third-quarter estimates and raised its guidance early Wednesday, sending the stock to a new high of 254.41 before closing up 1.1% at 247.91. Actavis' (AGN) earnings, excluding one-time...
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58)
Pershing Square is Handed a Partial Win in Allergan Case
at The Street - Wed Nov 05, 8:14AM CST
Hedge fund can vote its shares at special shareholder meeting regarding Valeant bid, but may still face securities law claims.
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91)
These 5 Drugmakers' Earnings Excelled This Quarter
at Investor's Business Daily - Tue Nov 04, 7:14PM CST
Big pharma firms such as Alexion Pharmaceuticals and Biogen Idec continue to outperform the market as they develop and market new treatments to treat long-time targets such as Alzheimer's as well as rare illnesses. Today's Screen Of The Day is Big...
AGN: 195.43 (-0.57), BIIB: 326.05 (+5.30), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58), JAZZ: 173.18 (+2.38), ALXN: 194.40 (+0.59), CELG: 107.77 (+1.32)
Allergan takeover closer?
at Investor's Business Daily - Tue Nov 04, 5:52PM CST
Valeant's (VRX) hostile takeover of the Botox maker may be closer now that a federal judge denied Allergan's (AGN) request to stop activist investor Bill Ackman and his Pershing Square Capital Management from voting against board members opposed to...
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91)
Allergan deal inches forward with court's decision
By The Associated Press - AP - Tue Nov 04, 3:59PM CST
In a win for Valeant and Pershing Square, a federal judge has decided that they can vote in takeover target Allergan's upcoming shareholder meeting.
VRX: 128.02 (+1.91), VRX.TO: 145.54 (+2.70)
Video: Top 3 Earnings Reports To Watch Wednesday
at Investor's Business Daily - Tue Nov 04, 12:45PM CST
Several highly rated tech companies and drugmakers are set to report earnings on Wednesday. Here's a look at what analysts expect. Actavis (ACT) reports its results before the open. The specialty-drug giant is projected to earn $3.10 a share, a 48%...
AGN: 195.43 (-0.57), TSLA: 241.92 (+1.72), VRX: 128.02 (+1.91), ACT: 246.49 (+0.58), ATHM: 44.38 (+0.75)
Valeant And Pershing Square May Vote At Special Meeting
CNW Group - Tue Nov 04, 12:27PM CST
Today, the United States District Court for the Central District of California held that Pershing Square Capital Management, L.P., Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and related parties may vote shares of Allergan, Inc. (NYSE: AGN) or proxies at the upcoming December 18 stockholder meeting. Allergan had sought to disenfranchise its largest shareholder, PS Fund 1, along with other shareholders solicited by PS Fund 1, by seeking an injunction to prevent them from voting at Allergan's December 18 special meeting. Today's ruling by Judge David O. Carter means that all Allergan shareholders, including PS Fund 1, will be permitted to have their voices heard by voting at the special meeting.
AGN: 195.43 (-0.57), VRX: 128.02 (+1.91), VRX.TO: 145.54 (+2.70)
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:50AM CST
Zoetis' (ZTS) third-quarter 2014 earnings (excluding special items) of 41 cents per share were above the Zacks Consensus Estimate of 37 cents.
ZTS: 40.18 (-0.05), ENDP: 68.89 (-0.07), VRX: 128.02 (+1.91), PFE: 30.24 (+0.32)
Stock Market News for November 03, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 9:10AM CST
Bank of Japan’s unanticipated expansion in monetary stimulus helped benchmarks to finish at record highs on Friday
VRX: 128.02 (+1.91), HAL: 53.76 (-0.10), XOM: 96.39 (-0.20), SLB: 99.18 (+0.45), YHOO: 49.22 (+0.67), GS: 191.58 (+0.87), V: 249.61 (-2.82), CMI: 146.19 (+0.15), CHK: 23.09 (-0.32), MRK: 58.99 (-0.35), EOG: 99.55 (unch), ABBV: 63.55 (+2.05), CAT: 102.40 (+0.64), CVX: 117.86 (-0.94), AAPL: 108.99 (-0.02), MA: 84.79 (-0.01)
Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter
PR Newswire - Mon Nov 03, 8:15AM CST
Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.
CI: 101.28 (+2.29), VRX: 128.02 (+1.91), BAX: 70.54 (-0.07), CVS: 89.02 (+0.64), REGN: 382.73 (+4.89)
